Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Lilly

Newer products contribute to growth in the quarter, while U.S. tax reform results in loss

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
4Q Revenues: $6.2 billion (+7%)
4Q Loss: $1.7 billion (earnings were $771.8 million 4Q16)
FY Revenues: $22.9 billion (+8%)
FY Loss: $204.1 million (earnings were $2.7 billion FY16)
Comments: Newer products contributed to growth in the quarter. Trulicity sales were $649.0 million, up 93%. Cyramza sales were $204.8 million, up 16%. Basaglar sales were $153.8 million, up 289%. Taltz sales were $172.5 million, up 182%. Jardiance sales were $143.2 million, up 88%. Growth in the quarter was offset by Strattera (down 60% to $98.3 million) and Effient (down 56% to $62.3 million) due to loss of exclusivity. Humalog sales were $782.2 million in the quarter, down 5% due to lower pricing. Cialis sales were $597.4 million, down 12% as a result of decreased demand. Forteo sales were up 21% in the quarter to $513.2 million. Humulin sales were $362.6 million, up 2%. Results in the quarter include an estimated charge of $1.9 billion associated with recently enacted U.S. tax reform legislation and charges associated with the company’s restructuring.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters